More than 40% of people with Down's syndrome in the UK are aged 40 years or older, and one in 10 of these individuals develops Alzheimer's disease. This rate rises to one in three of those who are older than 50 years and more than half of those older than 60 years. This progression is very distressing for parents and family carers because it can come at a time when—facing the physical and social challenges of ageing—they are least able to provide care, resulting in high caregiver burden. Thus, the MEADOWS trial reported by Marisa Hanney and colleagues in The Lancet is an important attempt to improve outcomes of adults with Down's syndrome and Alzheimer's disease. (Source: LANCET)

Läs hela artikeln: http://www.medworm.com/index.php?rid=5677657&cid=u_0_22_f&fid=30418&url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61929-6/fulltext?rss=yes

< Föregående		Nästa >